nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—XDH—Carboplatin—esophageal cancer	0.207	0.496	CbGbCtD
Trifluoperazine—ABCB1—esophageal cancer	0.203	1	CbGaD
Trifluoperazine—XDH—Cisplatin—esophageal cancer	0.177	0.424	CbGbCtD
Trifluoperazine—Carpo-pedal spasm—Cisplatin—esophageal cancer	0.0289	0.349	CcSEcCtD
Trifluoperazine—ABCB1—Cisplatin—esophageal cancer	0.0202	0.0483	CbGbCtD
Trifluoperazine—ABCB1—Methotrexate—esophageal cancer	0.0131	0.0314	CbGbCtD
Trifluoperazine—S100A4—exocrine gland—esophageal cancer	0.00806	0.0849	CbGeAlD
Trifluoperazine—S100A4—neck—esophageal cancer	0.00515	0.0543	CbGeAlD
Trifluoperazine—EBPL—epithelium—esophageal cancer	0.00444	0.0468	CbGeAlD
Trifluoperazine—HTR2A—vagus nerve—esophageal cancer	0.0041	0.0432	CbGeAlD
Trifluoperazine—S100A4—epithelium—esophageal cancer	0.00351	0.037	CbGeAlD
Trifluoperazine—S100A4—bronchus—esophageal cancer	0.00345	0.0364	CbGeAlD
Trifluoperazine—S100A4—smooth muscle tissue—esophageal cancer	0.00338	0.0356	CbGeAlD
Trifluoperazine—Megacolon—Methotrexate—esophageal cancer	0.00334	0.0404	CcSEcCtD
Trifluoperazine—S100A4—trachea—esophageal cancer	0.0031	0.0327	CbGeAlD
Trifluoperazine—Tetany—Cisplatin—esophageal cancer	0.00307	0.0371	CcSEcCtD
Trifluoperazine—EBPL—lung—esophageal cancer	0.00282	0.0297	CbGeAlD
Trifluoperazine—S100A4—digestive system—esophageal cancer	0.00267	0.0281	CbGeAlD
Trifluoperazine—UGT1A4—digestive system—esophageal cancer	0.00234	0.0247	CbGeAlD
Trifluoperazine—CALM2—exocrine gland—esophageal cancer	0.00232	0.0245	CbGeAlD
Trifluoperazine—CALM1—exocrine gland—esophageal cancer	0.00231	0.0243	CbGeAlD
Trifluoperazine—S100A4—lung—esophageal cancer	0.00223	0.0235	CbGeAlD
Trifluoperazine—Pigmentation disorder—Capecitabine—esophageal cancer	0.00221	0.0267	CcSEcCtD
Trifluoperazine—Trismus—Capecitabine—esophageal cancer	0.00221	0.0267	CcSEcCtD
Trifluoperazine—EBPL—lymph node—esophageal cancer	0.00193	0.0203	CbGeAlD
Trifluoperazine—TNNC1—lung—esophageal cancer	0.00187	0.0198	CbGeAlD
Trifluoperazine—CALY—lymph node—esophageal cancer	0.00176	0.0186	CbGeAlD
Trifluoperazine—XDH—digestive system—esophageal cancer	0.00171	0.018	CbGeAlD
Trifluoperazine—Ileus paralytic—Capecitabine—esophageal cancer	0.0017	0.0206	CcSEcCtD
Trifluoperazine—Retinal disorder—Methotrexate—esophageal cancer	0.00154	0.0186	CcSEcCtD
Trifluoperazine—S100A4—lymph node—esophageal cancer	0.00152	0.0161	CbGeAlD
Trifluoperazine—CALM2—neck—esophageal cancer	0.00148	0.0156	CbGeAlD
Trifluoperazine—CALM1—neck—esophageal cancer	0.00148	0.0156	CbGeAlD
Trifluoperazine—Sudden death—Capecitabine—esophageal cancer	0.00144	0.0174	CcSEcCtD
Trifluoperazine—TNNC1—lymph node—esophageal cancer	0.00128	0.0135	CbGeAlD
Trifluoperazine—CALM3—bronchus—esophageal cancer	0.00127	0.0133	CbGeAlD
Trifluoperazine—CALM3—smooth muscle tissue—esophageal cancer	0.00124	0.0131	CbGeAlD
Trifluoperazine—Liver injury—Cisplatin—esophageal cancer	0.00119	0.0144	CcSEcCtD
Trifluoperazine—CALM3—trachea—esophageal cancer	0.00114	0.012	CbGeAlD
Trifluoperazine—SIGMAR1—bronchus—esophageal cancer	0.00113	0.0119	CbGeAlD
Trifluoperazine—SIGMAR1—smooth muscle tissue—esophageal cancer	0.00111	0.0117	CbGeAlD
Trifluoperazine—Sudden death—Methotrexate—esophageal cancer	0.00107	0.013	CcSEcCtD
Trifluoperazine—Antrafenine—PTGS1—esophageal cancer	0.00105	0.312	CrCbGaD
Trifluoperazine—Torsade de pointes—Capecitabine—esophageal cancer	0.00105	0.0127	CcSEcCtD
Trifluoperazine—Ileus—Capecitabine—esophageal cancer	0.00104	0.0126	CcSEcCtD
Trifluoperazine—SIGMAR1—trachea—esophageal cancer	0.00102	0.0107	CbGeAlD
Trifluoperazine—CALM2—epithelium—esophageal cancer	0.00101	0.0106	CbGeAlD
Trifluoperazine—CALM1—epithelium—esophageal cancer	0.001	0.0106	CbGeAlD
Trifluoperazine—Hepatocellular injury—Cisplatin—esophageal cancer	0.001	0.0121	CcSEcCtD
Trifluoperazine—CALM2—bronchus—esophageal cancer	0.000994	0.0105	CbGeAlD
Trifluoperazine—CALM1—bronchus—esophageal cancer	0.000989	0.0104	CbGeAlD
Trifluoperazine—CALM2—smooth muscle tissue—esophageal cancer	0.000972	0.0102	CbGeAlD
Trifluoperazine—CALM1—smooth muscle tissue—esophageal cancer	0.000968	0.0102	CbGeAlD
Trifluoperazine—Body temperature increased—Carboplatin—esophageal cancer	0.000961	0.0116	CcSEcCtD
Trifluoperazine—ADRA1A—epithelium—esophageal cancer	0.000946	0.00998	CbGeAlD
Trifluoperazine—HTR2A—neck—esophageal cancer	0.000899	0.00948	CbGeAlD
Trifluoperazine—CALM2—trachea—esophageal cancer	0.000892	0.00941	CbGeAlD
Trifluoperazine—CALM1—trachea—esophageal cancer	0.000888	0.00936	CbGeAlD
Trifluoperazine—CALM3—lung—esophageal cancer	0.000816	0.00861	CbGeAlD
Trifluoperazine—Haemolytic anaemia—Cisplatin—esophageal cancer	0.000804	0.00971	CcSEcCtD
Trifluoperazine—Nasal congestion—Cisplatin—esophageal cancer	0.000797	0.00963	CcSEcCtD
Trifluoperazine—CALM2—digestive system—esophageal cancer	0.000768	0.00809	CbGeAlD
Trifluoperazine—CALM1—digestive system—esophageal cancer	0.000764	0.00806	CbGeAlD
Trifluoperazine—Gait disturbance—Capecitabine—esophageal cancer	0.000755	0.00912	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00075	0.00906	CcSEcCtD
Trifluoperazine—HRH1—epithelium—esophageal cancer	0.000733	0.00772	CbGeAlD
Trifluoperazine—SIGMAR1—lung—esophageal cancer	0.00073	0.00769	CbGeAlD
Trifluoperazine—HRH1—smooth muscle tissue—esophageal cancer	0.000706	0.00744	CbGeAlD
Trifluoperazine—HRH1—trachea—esophageal cancer	0.000648	0.00683	CbGeAlD
Trifluoperazine—CALM2—lung—esophageal cancer	0.000641	0.00676	CbGeAlD
Trifluoperazine—CALM1—lung—esophageal cancer	0.000638	0.00673	CbGeAlD
Trifluoperazine—HTR2A—epithelium—esophageal cancer	0.000612	0.00645	CbGeAlD
Trifluoperazine—Photosensitivity—Capecitabine—esophageal cancer	0.000609	0.00736	CcSEcCtD
Trifluoperazine—Antrafenine—PTGS2—esophageal cancer	0.000601	0.178	CrCbGaD
Trifluoperazine—Pancytopenia—Cisplatin—esophageal cancer	0.000596	0.0072	CcSEcCtD
Trifluoperazine—CYP1A2—digestive system—esophageal cancer	0.000595	0.00628	CbGeAlD
Trifluoperazine—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000593	0.00716	CcSEcCtD
Trifluoperazine—HTR2A—smooth muscle tissue—esophageal cancer	0.00059	0.00622	CbGeAlD
Trifluoperazine—DRD2—lung—esophageal cancer	0.000589	0.00621	CbGeAlD
Trifluoperazine—Increased appetite—Capecitabine—esophageal cancer	0.000569	0.00688	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000567	0.00685	CcSEcCtD
Trifluoperazine—CALM3—lymph node—esophageal cancer	0.000558	0.00589	CbGeAlD
Trifluoperazine—HRH1—digestive system—esophageal cancer	0.000557	0.00588	CbGeAlD
Trifluoperazine—HTR2A—trachea—esophageal cancer	0.000541	0.0057	CbGeAlD
Trifluoperazine—Aplastic anaemia—Methotrexate—esophageal cancer	0.000515	0.00622	CcSEcCtD
Trifluoperazine—Cardiac arrest—Capecitabine—esophageal cancer	0.000509	0.00615	CcSEcCtD
Trifluoperazine—Urinary retention—Capecitabine—esophageal cancer	0.000509	0.00615	CcSEcCtD
Trifluoperazine—SIGMAR1—lymph node—esophageal cancer	0.000499	0.00526	CbGeAlD
Trifluoperazine—CYP1A2—lung—esophageal cancer	0.000497	0.00524	CbGeAlD
Trifluoperazine—Gynaecomastia—Methotrexate—esophageal cancer	0.000491	0.00593	CcSEcCtD
Trifluoperazine—Muscular weakness—Capecitabine—esophageal cancer	0.000472	0.0057	CcSEcCtD
Trifluoperazine—HTR2A—digestive system—esophageal cancer	0.000465	0.00491	CbGeAlD
Trifluoperazine—HRH1—lung—esophageal cancer	0.000465	0.00491	CbGeAlD
Trifluoperazine—Asthma—Capecitabine—esophageal cancer	0.000462	0.00559	CcSEcCtD
Trifluoperazine—Dysphagia—Capecitabine—esophageal cancer	0.000462	0.00559	CcSEcCtD
Trifluoperazine—Bronchospasm—Capecitabine—esophageal cancer	0.000455	0.0055	CcSEcCtD
Trifluoperazine—Photosensitivity—Methotrexate—esophageal cancer	0.000454	0.00548	CcSEcCtD
Trifluoperazine—Pancytopenia—Capecitabine—esophageal cancer	0.000439	0.00531	CcSEcCtD
Trifluoperazine—CALM2—lymph node—esophageal cancer	0.000438	0.00462	CbGeAlD
Trifluoperazine—Erythema—Cisplatin—esophageal cancer	0.000437	0.00528	CcSEcCtD
Trifluoperazine—CALM1—lymph node—esophageal cancer	0.000436	0.0046	CbGeAlD
Trifluoperazine—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000422	0.0051	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000422	0.0051	CcSEcCtD
Trifluoperazine—Weight increased—Capecitabine—esophageal cancer	0.000421	0.00508	CcSEcCtD
Trifluoperazine—Muscle spasms—Cisplatin—esophageal cancer	0.00042	0.00508	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Capecitabine—esophageal cancer	0.000417	0.00504	CcSEcCtD
Trifluoperazine—Vision blurred—Cisplatin—esophageal cancer	0.000412	0.00498	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000411	0.00497	CcSEcCtD
Trifluoperazine—Tremor—Cisplatin—esophageal cancer	0.000409	0.00495	CcSEcCtD
Trifluoperazine—Jaundice—Capecitabine—esophageal cancer	0.000402	0.00486	CcSEcCtD
Trifluoperazine—ABCB1—epithelium—esophageal cancer	0.000401	0.00423	CbGeAlD
Trifluoperazine—Leukopenia—Cisplatin—esophageal cancer	0.000391	0.00473	CcSEcCtD
Trifluoperazine—HTR2A—lung—esophageal cancer	0.000389	0.0041	CbGeAlD
Trifluoperazine—Agranulocytosis—Capecitabine—esophageal cancer	0.000385	0.00465	CcSEcCtD
Trifluoperazine—Convulsion—Cisplatin—esophageal cancer	0.000379	0.00458	CcSEcCtD
Trifluoperazine—Oedema peripheral—Capecitabine—esophageal cancer	0.000365	0.0044	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000357	0.00431	CcSEcCtD
Trifluoperazine—ABCB1—trachea—esophageal cancer	0.000355	0.00374	CbGeAlD
Trifluoperazine—Skin disorder—Cisplatin—esophageal cancer	0.000346	0.00419	CcSEcCtD
Trifluoperazine—Asthma—Methotrexate—esophageal cancer	0.000344	0.00416	CcSEcCtD
Trifluoperazine—Eosinophilia—Methotrexate—esophageal cancer	0.000341	0.00412	CcSEcCtD
Trifluoperazine—Anorexia—Cisplatin—esophageal cancer	0.00034	0.00411	CcSEcCtD
Trifluoperazine—Hypotension—Cisplatin—esophageal cancer	0.000333	0.00403	CcSEcCtD
Trifluoperazine—Pancytopenia—Methotrexate—esophageal cancer	0.000327	0.00395	CcSEcCtD
Trifluoperazine—Erythema—Capecitabine—esophageal cancer	0.000322	0.00389	CcSEcCtD
Trifluoperazine—HRH1—lymph node—esophageal cancer	0.000318	0.00336	CbGeAlD
Trifluoperazine—Dyspnoea—Cisplatin—esophageal cancer	0.000318	0.00384	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Methotrexate—esophageal cancer	0.000317	0.00383	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000314	0.0038	CcSEcCtD
Trifluoperazine—Decreased appetite—Cisplatin—esophageal cancer	0.00031	0.00375	CcSEcCtD
Trifluoperazine—Muscle spasms—Capecitabine—esophageal cancer	0.00031	0.00374	CcSEcCtD
Trifluoperazine—Drowsiness—Methotrexate—esophageal cancer	0.000307	0.00371	CcSEcCtD
Trifluoperazine—ABCB1—digestive system—esophageal cancer	0.000305	0.00322	CbGeAlD
Trifluoperazine—Vision blurred—Capecitabine—esophageal cancer	0.000304	0.00367	CcSEcCtD
Trifluoperazine—Tremor—Capecitabine—esophageal cancer	0.000302	0.00365	CcSEcCtD
Trifluoperazine—Leukopenia—Capecitabine—esophageal cancer	0.000288	0.00348	CcSEcCtD
Trifluoperazine—Agranulocytosis—Methotrexate—esophageal cancer	0.000286	0.00346	CcSEcCtD
Trifluoperazine—Body temperature increased—Cisplatin—esophageal cancer	0.000282	0.00341	CcSEcCtD
Trifluoperazine—Cough—Capecitabine—esophageal cancer	0.000281	0.0034	CcSEcCtD
Trifluoperazine—Flupentixol—ABCB1—esophageal cancer	0.00027	0.0803	CrCbGaD
Trifluoperazine—Dry mouth—Capecitabine—esophageal cancer	0.000268	0.00324	CcSEcCtD
Trifluoperazine—Clozapine—CYP1B1—esophageal cancer	0.000263	0.0781	CrCbGaD
Trifluoperazine—Hypersensitivity—Cisplatin—esophageal cancer	0.000263	0.00318	CcSEcCtD
Trifluoperazine—Asthenia—Cisplatin—esophageal cancer	0.000256	0.00309	CcSEcCtD
Trifluoperazine—Skin disorder—Capecitabine—esophageal cancer	0.000255	0.00309	CcSEcCtD
Trifluoperazine—ABCB1—lung—esophageal cancer	0.000255	0.00269	CbGeAlD
Trifluoperazine—Anorexia—Capecitabine—esophageal cancer	0.000251	0.00303	CcSEcCtD
Trifluoperazine—Hypotension—Capecitabine—esophageal cancer	0.000246	0.00297	CcSEcCtD
Trifluoperazine—Erythema—Methotrexate—esophageal cancer	0.00024	0.0029	CcSEcCtD
Trifluoperazine—Insomnia—Capecitabine—esophageal cancer	0.000238	0.00287	CcSEcCtD
Trifluoperazine—Dyspnoea—Capecitabine—esophageal cancer	0.000234	0.00283	CcSEcCtD
Trifluoperazine—Decreased appetite—Capecitabine—esophageal cancer	0.000229	0.00276	CcSEcCtD
Trifluoperazine—Fatigue—Capecitabine—esophageal cancer	0.000227	0.00274	CcSEcCtD
Trifluoperazine—Vision blurred—Methotrexate—esophageal cancer	0.000226	0.00273	CcSEcCtD
Trifluoperazine—Rash—Cisplatin—esophageal cancer	0.000225	0.00272	CcSEcCtD
Trifluoperazine—Constipation—Capecitabine—esophageal cancer	0.000225	0.00272	CcSEcCtD
Trifluoperazine—Dermatitis—Cisplatin—esophageal cancer	0.000225	0.00271	CcSEcCtD
Trifluoperazine—Leukopenia—Methotrexate—esophageal cancer	0.000215	0.00259	CcSEcCtD
Trifluoperazine—Nausea—Cisplatin—esophageal cancer	0.000212	0.00256	CcSEcCtD
Trifluoperazine—Cough—Methotrexate—esophageal cancer	0.000209	0.00253	CcSEcCtD
Trifluoperazine—Urticaria—Capecitabine—esophageal cancer	0.000209	0.00252	CcSEcCtD
Trifluoperazine—Body temperature increased—Capecitabine—esophageal cancer	0.000208	0.00251	CcSEcCtD
Trifluoperazine—Convulsion—Methotrexate—esophageal cancer	0.000208	0.00251	CcSEcCtD
Trifluoperazine—Clozapine—CYP2A6—esophageal cancer	0.000203	0.0602	CrCbGaD
Trifluoperazine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000196	0.00236	CcSEcCtD
Trifluoperazine—Hypersensitivity—Capecitabine—esophageal cancer	0.000194	0.00234	CcSEcCtD
Trifluoperazine—Skin disorder—Methotrexate—esophageal cancer	0.00019	0.0023	CcSEcCtD
Trifluoperazine—Asthenia—Capecitabine—esophageal cancer	0.000189	0.00228	CcSEcCtD
Trifluoperazine—Anorexia—Methotrexate—esophageal cancer	0.000187	0.00225	CcSEcCtD
Trifluoperazine—Pruritus—Capecitabine—esophageal cancer	0.000186	0.00225	CcSEcCtD
Trifluoperazine—Hypotension—Methotrexate—esophageal cancer	0.000183	0.00221	CcSEcCtD
Trifluoperazine—Insomnia—Methotrexate—esophageal cancer	0.000177	0.00214	CcSEcCtD
Trifluoperazine—Dyspnoea—Methotrexate—esophageal cancer	0.000174	0.00211	CcSEcCtD
Trifluoperazine—ABCB1—lymph node—esophageal cancer	0.000174	0.00184	CbGeAlD
Trifluoperazine—Somnolence—Methotrexate—esophageal cancer	0.000174	0.0021	CcSEcCtD
Trifluoperazine—Dizziness—Capecitabine—esophageal cancer	0.000174	0.0021	CcSEcCtD
Trifluoperazine—Decreased appetite—Methotrexate—esophageal cancer	0.00017	0.00206	CcSEcCtD
Trifluoperazine—Fatigue—Methotrexate—esophageal cancer	0.000169	0.00204	CcSEcCtD
Trifluoperazine—Rash—Capecitabine—esophageal cancer	0.000166	0.002	CcSEcCtD
Trifluoperazine—Dermatitis—Capecitabine—esophageal cancer	0.000166	0.002	CcSEcCtD
Trifluoperazine—Headache—Capecitabine—esophageal cancer	0.000165	0.00199	CcSEcCtD
Trifluoperazine—Nausea—Capecitabine—esophageal cancer	0.000156	0.00189	CcSEcCtD
Trifluoperazine—Urticaria—Methotrexate—esophageal cancer	0.000155	0.00188	CcSEcCtD
Trifluoperazine—Body temperature increased—Methotrexate—esophageal cancer	0.000155	0.00187	CcSEcCtD
Trifluoperazine—Nefazodone—ABCB1—esophageal cancer	0.000151	0.0449	CrCbGaD
Trifluoperazine—Triflupromazine—ABCB1—esophageal cancer	0.000147	0.0437	CrCbGaD
Trifluoperazine—Hypersensitivity—Methotrexate—esophageal cancer	0.000144	0.00174	CcSEcCtD
Trifluoperazine—Asthenia—Methotrexate—esophageal cancer	0.00014	0.0017	CcSEcCtD
Trifluoperazine—Trazodone—ABCB1—esophageal cancer	0.00014	0.0415	CrCbGaD
Trifluoperazine—Pruritus—Methotrexate—esophageal cancer	0.000138	0.00167	CcSEcCtD
Trifluoperazine—Dizziness—Methotrexate—esophageal cancer	0.000129	0.00156	CcSEcCtD
Trifluoperazine—Rash—Methotrexate—esophageal cancer	0.000123	0.00149	CcSEcCtD
Trifluoperazine—Dermatitis—Methotrexate—esophageal cancer	0.000123	0.00149	CcSEcCtD
Trifluoperazine—Headache—Methotrexate—esophageal cancer	0.000123	0.00148	CcSEcCtD
Trifluoperazine—Nausea—Methotrexate—esophageal cancer	0.000116	0.0014	CcSEcCtD
Trifluoperazine—Fluphenazine—ABCB1—esophageal cancer	0.000113	0.0336	CrCbGaD
Trifluoperazine—Clomipramine—ABCB1—esophageal cancer	0.000104	0.0307	CrCbGaD
Trifluoperazine—Promethazine—ABCB1—esophageal cancer	9.18e-05	0.0272	CrCbGaD
Trifluoperazine—Quetiapine—ABCB1—esophageal cancer	8.78e-05	0.0261	CrCbGaD
Trifluoperazine—Clozapine—ABCB1—esophageal cancer	7.55e-05	0.0224	CrCbGaD
Trifluoperazine—Chlorpromazine—ABCB1—esophageal cancer	7.1e-05	0.0211	CrCbGaD
Trifluoperazine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	6.83e-06	3.44e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—HIF1A—esophageal cancer	6.82e-06	3.43e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—HIF1A—esophageal cancer	6.71e-06	3.37e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—SMAD4—esophageal cancer	6.7e-06	3.37e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—SMAD4—esophageal cancer	6.7e-06	3.37e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	6.69e-06	3.36e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—TP53—esophageal cancer	6.66e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—PIK3CA—esophageal cancer	6.66e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—PIK3CA—esophageal cancer	6.66e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—KDR—esophageal cancer	6.64e-06	3.34e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—EGFR—esophageal cancer	6.63e-06	3.34e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—EGFR—esophageal cancer	6.63e-06	3.34e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—CREBBP—esophageal cancer	6.62e-06	3.33e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—HMOX1—esophageal cancer	6.54e-06	3.29e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—KDR—esophageal cancer	6.53e-06	3.29e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—KDR—esophageal cancer	6.52e-06	3.28e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	6.46e-06	3.25e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—CCND1—esophageal cancer	6.46e-06	3.25e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—TP53—esophageal cancer	6.44e-06	3.24e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—TP53—esophageal cancer	6.44e-06	3.24e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	6.43e-06	3.23e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—KDR—esophageal cancer	6.42e-06	3.23e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—CREBBP—esophageal cancer	6.4e-06	3.22e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—CREBBP—esophageal cancer	6.4e-06	3.22e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—KDR—esophageal cancer	6.4e-06	3.22e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	6.35e-06	3.19e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	6.31e-06	3.18e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	6.26e-06	3.15e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—CDKN1A—esophageal cancer	6.25e-06	3.14e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—PIK3CA—esophageal cancer	6.2e-06	3.12e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—BCL2—esophageal cancer	6.18e-06	3.11e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.16e-06	3.1e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	6.15e-06	3.1e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	6.14e-06	3.09e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	6.09e-06	3.06e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	6.07e-06	3.05e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NOTCH1—esophageal cancer	6.04e-06	3.04e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	6.04e-06	3.04e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	6.03e-06	3.03e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—ERBB2—esophageal cancer	6e-06	3.02e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—PIK3CA—esophageal cancer	6e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—PIK3CA—esophageal cancer	6e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—BCL2—esophageal cancer	5.97e-06	3e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—BCL2—esophageal cancer	5.97e-06	3e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—PIK3CA—esophageal cancer	5.95e-06	2.99e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—EP300—esophageal cancer	5.94e-06	2.99e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—NOS3—esophageal cancer	5.92e-06	2.98e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—ERBB2—esophageal cancer	5.8e-06	2.92e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—ERBB2—esophageal cancer	5.8e-06	2.92e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—NOS3—esophageal cancer	5.78e-06	2.91e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—PIK3CA—esophageal cancer	5.76e-06	2.9e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—PIK3CA—esophageal cancer	5.76e-06	2.9e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	5.75e-06	2.89e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—NOS3—esophageal cancer	5.73e-06	2.88e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—NOS3—esophageal cancer	5.73e-06	2.88e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	5.73e-06	2.88e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CREBBP—esophageal cancer	5.67e-06	2.85e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—HIF1A—esophageal cancer	5.67e-06	2.85e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	5.58e-06	2.81e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—EGFR—esophageal cancer	5.57e-06	2.8e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CREBBP—esophageal cancer	5.57e-06	2.8e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—CREBBP—esophageal cancer	5.54e-06	2.79e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—ERBB2—esophageal cancer	5.54e-06	2.79e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	5.51e-06	2.77e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—HIF1A—esophageal cancer	5.49e-06	2.76e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—HIF1A—esophageal cancer	5.49e-06	2.76e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	5.48e-06	2.76e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	5.48e-06	2.76e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CREBBP—esophageal cancer	5.48e-06	2.76e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—EGFR—esophageal cancer	5.47e-06	2.75e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	5.46e-06	2.75e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KDR—esophageal cancer	5.42e-06	2.73e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—PTGS2—esophageal cancer	5.42e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	5.41e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—EGFR—esophageal cancer	5.38e-06	2.71e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	5.38e-06	2.71e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	5.37e-06	2.7e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—CREBBP—esophageal cancer	5.36e-06	2.7e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—CREBBP—esophageal cancer	5.36e-06	2.7e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—ERBB2—esophageal cancer	5.36e-06	2.69e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—ERBB2—esophageal cancer	5.36e-06	2.69e-05	CbGpPWpGaD
Trifluoperazine—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	5.33e-06	2.68e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KDR—esophageal cancer	5.25e-06	2.64e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KDR—esophageal cancer	5.25e-06	2.64e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	5.24e-06	2.64e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—PTGS2—esophageal cancer	5.24e-06	2.64e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—PTGS2—esophageal cancer	5.24e-06	2.64e-05	CbGpPWpGaD
Trifluoperazine—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	5.23e-06	2.63e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—HMOX1—esophageal cancer	5.22e-06	2.63e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—MYC—esophageal cancer	5.18e-06	2.6e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR downstream signaling—PIK3CA—esophageal cancer	5.15e-06	2.59e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	5.13e-06	2.58e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CDKN1A—esophageal cancer	5.13e-06	2.58e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.13e-06	2.58e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NOTCH1—esophageal cancer	5.11e-06	2.57e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—NOS3—esophageal cancer	5.08e-06	2.55e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—EGFR—esophageal cancer	5.07e-06	2.55e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—ABCB1—esophageal cancer	5.01e-06	2.52e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	5e-06	2.51e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—NOS3—esophageal cancer	4.99e-06	2.51e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CDKN1A—esophageal cancer	4.96e-06	2.49e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CDKN1A—esophageal cancer	4.96e-06	2.49e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—NOS3—esophageal cancer	4.96e-06	2.49e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NOTCH1—esophageal cancer	4.94e-06	2.49e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NOTCH1—esophageal cancer	4.94e-06	2.49e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NOS3—esophageal cancer	4.91e-06	2.47e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	4.89e-06	2.46e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—EP300—esophageal cancer	4.88e-06	2.45e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	4.84e-06	2.43e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—NOS3—esophageal cancer	4.8e-06	2.41e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—NOS3—esophageal cancer	4.8e-06	2.41e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CCND1—esophageal cancer	4.78e-06	2.4e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	4.76e-06	2.39e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	4.75e-06	2.39e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—ERBB2—esophageal cancer	4.75e-06	2.39e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	4.75e-06	2.39e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—CDKN1A—esophageal cancer	4.73e-06	2.38e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—EP300—esophageal cancer	4.72e-06	2.37e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—EP300—esophageal cancer	4.72e-06	2.37e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	4.67e-06	2.35e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—PIK3CA—esophageal cancer	4.67e-06	2.35e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—ERBB2—esophageal cancer	4.66e-06	2.35e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	4.66e-06	2.34e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CREBBP—esophageal cancer	4.63e-06	2.33e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	4.62e-06	2.33e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	4.6e-06	2.31e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—ERBB2—esophageal cancer	4.59e-06	2.31e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—CDKN1A—esophageal cancer	4.58e-06	2.3e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—CDKN1A—esophageal cancer	4.58e-06	2.3e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	4.58e-06	2.3e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—EGFR—esophageal cancer	4.55e-06	2.29e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PTGS2—esophageal cancer	4.54e-06	2.28e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—EP300—esophageal cancer	4.51e-06	2.27e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CREBBP—esophageal cancer	4.48e-06	2.25e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CREBBP—esophageal cancer	4.48e-06	2.25e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—EGFR—esophageal cancer	4.4e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—EGFR—esophageal cancer	4.4e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—EP300—esophageal cancer	4.4e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	4.4e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PTGS2—esophageal cancer	4.39e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PTGS2—esophageal cancer	4.39e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—EP300—esophageal cancer	4.38e-06	2.2e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—EP300—esophageal cancer	4.36e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—EP300—esophageal cancer	4.36e-06	2.19e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—TP53—esophageal cancer	4.25e-06	2.14e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—CREBBP—esophageal cancer	4.2e-06	2.11e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CCND1—esophageal cancer	4.2e-06	2.11e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—EGFR—esophageal cancer	4.16e-06	2.09e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NOS3—esophageal cancer	4.15e-06	2.09e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	4.13e-06	2.08e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CCND1—esophageal cancer	4.12e-06	2.07e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	4.06e-06	2.04e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CCND1—esophageal cancer	4.05e-06	2.04e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	4.04e-06	2.03e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—EGFR—esophageal cancer	4.02e-06	2.02e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—EGFR—esophageal cancer	4.02e-06	2.02e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NOS3—esophageal cancer	4.01e-06	2.02e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NOS3—esophageal cancer	4.01e-06	2.02e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	3.99e-06	2.01e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	3.99e-06	2e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—PIK3CA—esophageal cancer	3.95e-06	1.99e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MYC—esophageal cancer	3.93e-06	1.97e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CDKN1A—esophageal cancer	3.92e-06	1.97e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	3.91e-06	1.97e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—ERBB2—esophageal cancer	3.88e-06	1.95e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—EP300—esophageal cancer	3.86e-06	1.94e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—EGFR—esophageal cancer	3.84e-06	1.93e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MYC—esophageal cancer	3.83e-06	1.93e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—PIK3CA—esophageal cancer	3.82e-06	1.92e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—PIK3CA—esophageal cancer	3.82e-06	1.92e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MYC—esophageal cancer	3.81e-06	1.92e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—EP300—esophageal cancer	3.8e-06	1.91e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MYC—esophageal cancer	3.8e-06	1.91e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MYC—esophageal cancer	3.8e-06	1.91e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—EP300—esophageal cancer	3.79e-06	1.91e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.79e-06	1.91e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—EP300—esophageal cancer	3.77e-06	1.9e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—NOS3—esophageal cancer	3.76e-06	1.89e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—ERBB2—esophageal cancer	3.75e-06	1.89e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—ERBB2—esophageal cancer	3.75e-06	1.89e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—EGFR—esophageal cancer	3.75e-06	1.89e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—EP300—esophageal cancer	3.73e-06	1.88e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	3.73e-06	1.88e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—EP300—esophageal cancer	3.72e-06	1.87e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—EGFR—esophageal cancer	3.71e-06	1.87e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—EGFR—esophageal cancer	3.71e-06	1.87e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—EP300—esophageal cancer	3.65e-06	1.84e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—EP300—esophageal cancer	3.65e-06	1.84e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—PIK3CA—esophageal cancer	3.61e-06	1.82e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—PIK3CA—esophageal cancer	3.49e-06	1.76e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—PIK3CA—esophageal cancer	3.49e-06	1.76e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PTGS2—esophageal cancer	3.44e-06	1.73e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CCND1—esophageal cancer	3.43e-06	1.72e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MYC—esophageal cancer	3.37e-06	1.69e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.35e-06	1.69e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—PIK3CA—esophageal cancer	3.33e-06	1.68e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CDKN1A—esophageal cancer	3.32e-06	1.67e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CCND1—esophageal cancer	3.32e-06	1.67e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CCND1—esophageal cancer	3.32e-06	1.67e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MYC—esophageal cancer	3.31e-06	1.67e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MYC—esophageal cancer	3.3e-06	1.66e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—EGFR—esophageal cancer	3.29e-06	1.66e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	3.25e-06	1.64e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MYC—esophageal cancer	3.25e-06	1.64e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MYC—esophageal cancer	3.24e-06	1.63e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	3.24e-06	1.63e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	3.24e-06	1.63e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—EGFR—esophageal cancer	3.23e-06	1.63e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—PIK3CA—esophageal cancer	3.22e-06	1.62e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—PIK3CA—esophageal cancer	3.22e-06	1.62e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CDKN1A—esophageal cancer	3.21e-06	1.61e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CDKN1A—esophageal cancer	3.21e-06	1.61e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—EGFR—esophageal cancer	3.18e-06	1.6e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	3.17e-06	1.6e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—EP300—esophageal cancer	3.15e-06	1.59e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TP53—esophageal cancer	3.15e-06	1.58e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TP53—esophageal cancer	3.13e-06	1.58e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—EP300—esophageal cancer	3.05e-06	1.53e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—EP300—esophageal cancer	3.05e-06	1.53e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—NOS3—esophageal cancer	3e-06	1.51e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—EP300—esophageal cancer	2.86e-06	1.44e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	2.86e-06	1.44e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	2.81e-06	1.41e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	2.81e-06	1.41e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PIK3CA—esophageal cancer	2.79e-06	1.4e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TP53—esophageal cancer	2.76e-06	1.39e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PIK3CA—esophageal cancer	2.76e-06	1.39e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	2.75e-06	1.38e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MYC—esophageal cancer	2.75e-06	1.38e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.74e-06	1.38e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TP53—esophageal cancer	2.72e-06	1.37e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TP53—esophageal cancer	2.71e-06	1.36e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PIK3CA—esophageal cancer	2.7e-06	1.36e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PIK3CA—esophageal cancer	2.7e-06	1.36e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—EGFR—esophageal cancer	2.69e-06	1.35e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TP53—esophageal cancer	2.67e-06	1.34e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TP53—esophageal cancer	2.66e-06	1.34e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MYC—esophageal cancer	2.66e-06	1.34e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MYC—esophageal cancer	2.66e-06	1.34e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—EGFR—esophageal cancer	2.6e-06	1.31e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—EGFR—esophageal cancer	2.6e-06	1.31e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PIK3CA—esophageal cancer	2.33e-06	1.17e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—EP300—esophageal cancer	2.28e-06	1.15e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TP53—esophageal cancer	2.26e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PIK3CA—esophageal cancer	2.26e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PIK3CA—esophageal cancer	2.26e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TP53—esophageal cancer	2.18e-06	1.1e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TP53—esophageal cancer	2.18e-06	1.1e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.12e-06	1.06e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.69e-06	8.49e-06	CbGpPWpGaD
